Skip to content

A prospective randomized clinical study of resection of the caudate lobe in the hilar cholangiocarcinoma .

A prospective randomized clinical study of whether or not resection of the caudate lobe in the hilar cholangiocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012980
Enrollment
Unknown
Registered
2017-10-14
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hilar cholangiocarcinoma

Interventions

Group 1:Both biliary resection and caudate lobectomy
Group 2:biliary resection only

Sponsors

Eastern Hepatobiliary Hospital, Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male and female under 70 years of age; 2. ECOG score=2; 3. Diagosis of hilar cholangiocarcinoma before operation(Bismuth I-II); 4. The imaging examination showed that the radical resection of the tumor could be performed preoperatively; 5. The tumor mainly located in the central region of porta hepatis, tumor were not invade the liver parenchyma, portal vein, and its bifurcation; 6. No metastasis of distant lymph nodes, such as the mesenteric root could be found; 7. Willing and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. During the operation, bilateral liver metastasis, distant organ metastasis or peritoneal metastasis were found; 2. The metastasis of lymph node has exceeded the scope of radical resection; 3. Tumor invaded the branches of bilateral bile duct, and radical resection could not be performed; 4. Bilateral or bifurcation or the trunk of the portal vein are extensively invaded, and vascular reconstruction cannot be performed; 5. A large amount of ascites was found during the operation, and the patient could not tolerate any major operation; 6. There are any other serious diseases that may affect the patient's treatment, follow-up or evaluation, Including heart, lung, kidney, digestive, nervous, mental, immune, metabolic, and infectious diseases.

Design outcomes

Primary

MeasureTime frame
Time to recurrence;overall survival;

Countries

China

Contacts

Public ContactYongjie Zhang

Eastern Hepatobiliary Hospital, Second Military Medical University

yjoy005@sina.com+86 021-81875271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026